Scientists are mentioned in their findings and published in the journal "لانست" Medical that 23 percent of those who took pharmaceutical They died within 28 days of starting the treatment, compared to 22% of those who received the usual care, noting that the trial included 1616 patients who took "Lopinavir" And"Ritonavir", And 3,242 received only standard care.
The treatment also did not reduce the length of the patient’s stay in the hospital or the chances of putting him on a ventilator, as reported "Reuters".
Commenting on the study, Martin Landray, professor in the Nuffield Department of Population Health at Oxford University who co-led the trial, said "ركفري": "The results of this trial demonstrate that it is an ineffective treatment for hospitalized patients with COVID-19".
And drug "Kaletra" Which is produced by a company "My father" It is a mixture of a real estate "Lopinavir" And"Ritonavir" They are used together to treat a virus"HIV".
The company had increased its production of the drug while determining whether it was useful in treating Covid-19, and it was discontinued World Health Organization In July, try it on a combination "Lopinavir" And"Ritonavir" After it failed to reduce deaths.
“>
He said British scientists are participating in a randomized evaluation trial of a treatment Covid-19 Known as “recovery” at the University Oxford In June, the provisional results convincingly ruled out any meaningful benefit of the drug lopinavir and ritonavir in reducing deaths among hospitalized patients.
And the scientists said in their findings and published in the medical journal “The Lancet” that 23 percent of those who took it pharmaceutical They died within 28 days of starting treatment, compared to 22 percent of those who received the usual care, noting that the trial included 1616 patients who took “lopinavir” and “ritonavir”, and 3242 received the usual care only.
The treatment also did not reduce the length of the patient’s stay in the hospital or the chances of him being placed on a ventilator, as quoted by “Reuters”.
Commenting on the study, Martin Landray, a professor in the Nuffield Department of Population Health at the University of Oxford who co-led the “recovery” trial, said: “The results of this trial demonstrate that it is an ineffective treatment for hospitalized patients with Covid-19.”
The drug “Kaletra” produced by “AbbVie” is a mixture of the drugs “lopinavir” and “ritonavir”, which are used together to treat the “HIV” virus.
The company had increased its production of the drug while determining whether it was useful in treating Covid-19, and it was discontinued World Health Organization In July, it tested the combination “lopinavir” and “ritonavir” after it failed to reduce mortality.
– .
